[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association]
- PMID: 23178093
- DOI: 10.1016/j.purol.2012.10.001
[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association]
Abstract
Aim: To elaborate guidelines for the diagnosis, the follow-up, and the treatment of benign prostatic hyperplasia (BPH).
Method: A systematic review of the literature was conducted to select more relevant publications. The level of evidence was evaluated. Graded recommendations were written by a working group, and then reviewed by a reviewer group according to the formalized consensus technique.
Results: Terminology of the International Continence Society was used. Initial assessment has several aims: making sure that lower urinary tract symptoms (LUTS) are related to BPH, assessing bother related to LUTS and checking for a possible complicated bladder outlet obstruction (BOO). Initial assessment should include: medical history, LUTS assessment using a symptomatic score, physical examination including digital rectal examination, urinalysis, flow rate recording, and residual urine volume. Frequency volume chart is recommended when storage symptoms are predominant. Serum PSA should be done when the diagnosis of prostate cancer can modify the management. When a surgical treatment is discussed, serum PSA, serum creatinine and ultrasonography of the urinary tract are recommended. BPH patients should be informed of the benign and possibly progressive patterns of the disease. When LUTS cause no bother, annual follow-up should be planned. Medical treatment includes some phytotherapy agents, alpha-blockers and 5-alpha reductase inhibitors. The last two can be associated. The association of antimuscarinics and alpha-blockers can be offered to patients with residual storage symptoms when already under alpha-blockers therapy, after checking for the absence of severe BOO (residual volume more than 200mL or max urinary flow less than 10mL/s). Phosphodiesterase-5 inhibitors could be used in patients complaining for both LUTS and erectile dysfunction. In case of complication, or when medical treatment is inefficient or not tolerated, then a surgical treatment should be discussed. Treatment decision should be done according to type of LUTS and related bother, prostate anatomy, level of obstruction and its consequences on urinary tract, patient co-morbidities, experience of practitioner, and choice of patient. Surgical treatments with the higher level of evidence of efficacy include monopolar or bipolar transurethral resection of the prostate, open prostatectomy, transurethral incision of the prostate, photoselective vaporization of the prostate, and Holmium laser enuclation of the prostate.
Conclusion: Here are the first guidelines of the French Urological Association for the initial assessment, the follow-up and the treatment of urinary disorders related to BPH.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.
Similar articles
-
[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].Prog Urol. 2015 Jun;25(7):404-12. doi: 10.1016/j.purol.2015.02.008. Epub 2015 Apr 2. Prog Urol. 2015. PMID: 25841758 French.
-
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.Eur Urol. 2013 Jul;64(1):118-40. doi: 10.1016/j.eururo.2013.03.004. Epub 2013 Mar 13. Eur Urol. 2013. PMID: 23541338 Review.
-
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007. Curr Opin Urol. 2014. PMID: 24231531 Review.
-
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Eur Urol. 2011. PMID: 21726934 Review.
-
Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.Clin Ther. 2006 Jan;28(1):13-25. doi: 10.1016/j.clinthera.2006.01.004. Clin Ther. 2006. PMID: 16490576 Review.
Cited by
-
Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study.Sci Rep. 2023 Mar 31;13(1):5308. doi: 10.1038/s41598-023-32356-3. Sci Rep. 2023. PMID: 37002313 Free PMC article.
-
Holmium Laser Enucleation of the Prostate versus Laparoscopic Transcapsular Prostatectomy: Perioperative Results and Three-Month Follow-Up.Curr Urol. 2017 Jul;10(2):81-86. doi: 10.1159/000447156. Epub 2017 May 30. Curr Urol. 2017. PMID: 28785192 Free PMC article.
-
Assessment of the learning curves for photoselective vaporization of the prostate using GreenLight™ 180-Watt-XPS laser therapy: defining the intra-operative parameters within a prospective cohort.World J Urol. 2014 Apr;32(2):539-44. doi: 10.1007/s00345-013-1163-7. Epub 2013 Sep 26. World J Urol. 2014. PMID: 24072009
-
Do patients have to choose between ejaculation and miction? A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment.World J Urol. 2019 Feb;37(2):299-308. doi: 10.1007/s00345-018-2368-6. Epub 2018 Jul 2. World J Urol. 2019. PMID: 29967947
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous